The failure of these clinical trials, including the most recent discontinuation of AstraZeneca/Eli Lilly’s Lanabecestat in phase III clinical trial, proposed that the early intervention of AD, even without any symptoms, may be necessary for the success of the BACE1 inhibitors [8,9]. Here, BACE1 is linked to Alzheimer disease.